HS-20094
Sources
registry, as of 2026-10-26Stale
https://clinicaltrials.gov/study/NCT07896265
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Regeneron Pharmaceuticals. Enrollment 3000. Conditions Overweight or Obesity Without Diabetes. This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight or obese but do not have diabetes. The study is lo
ClinicalTrials.gov NCT07896265 protocol and results modules
registry, as of 2026-06-08Stale
https://clinicaltrials.gov/study/NCT06839664
A Study of HS-20094 in Chinese Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.. Enrollment 604. Conditions Overweight; Obesity. The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.
ClinicalTrials.gov NCT06839664 protocol and results modules
registry, as of 2026-11-06
https://clinicaltrials.gov/study/NCT07685808
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes. Overall status RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 360. Conditions Overweight or Obesity. This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the
ClinicalTrials.gov NCT07685808 protocol and results modules
registry, as of 2026-09-21Stale
https://clinicaltrials.gov/study/NCT07830329
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 300. Conditions Hidradenitis Suppurativa. This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve thei
ClinicalTrials.gov NCT07830329 protocol and results modules
registry, as of 2026-06-04Stale
https://clinicaltrials.gov/study/NCT06118021
A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.. Enrollment 200. Conditions Overweight and Obesity. This is a study of HS-20094 in participants with overweight and obesity. The main purpose is to learn more about how HS-20094 affects body weight. The study period including 4-12 weeks dose titration and 12-20 weeks maintain treatment and 6 weeks follow up.
ClinicalTrials.gov NCT06118021 protocol and results modules
registry, as of 2026-06-17Stale
https://clinicaltrials.gov/study/NCT07431086
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 120. Conditions Overweight or Obesity. This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study wil
ClinicalTrials.gov NCT07431086 protocol and results modules
registry, as of 2025-07-10Stale
https://clinicaltrials.gov/study/NCT07057674
A Study of HS-20094 in Overweight or Obese Participants. Overall status RECRUITING. Phases PHASE1. Lead sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.. Enrollment 144. Conditions Overweight or Obesity. This is a multicenter, randomized, open-label, parallel clinical study to evaluate the bioequivalence of the HS-20094 MDV pen and AI pen in overweight or obese subjects.
ClinicalTrials.gov NCT07057674 protocol and results modules